Akumin: peers
Akumin beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.
Akumin, Biomark Diagnostics Inc., Medivolve Inc., Cognetivity Neurosciences Ltd., ASEP Medical Holdings Inc., Izotropic Corporation: the market cap on file is more than 60 days old or a last known value (no market-data feed for their exchanges yet), so their valuation multiples and yields are shown but not ranked.
Side by side#
Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.
| Measure | Akuminbase AKU.TO · 🇨🇦 CA Percentile in Healthcare Percentile in Canada | Biomark Diagnostics Inc. BUX.CN · 🇨🇦 CA Percentile in Healthcare Percentile in Canada | Medivolve Inc. 4NC.F · 🇨🇦 CA Percentile in Healthcare Percentile in Canada | Cognetivity Neurosciences Ltd. 1UB.F · 🇨🇦 CA Percentile in Healthcare Percentile in Canada | Bionano Genomics, Inc. BNGO · 🇺🇸 US Percentile in Healthcare Percentile in USA | ASEP Medical Holdings Inc. ASEP.CN · 🇨🇦 CA Percentile in Healthcare Percentile in Canada | Avricore Health Inc. AVCR.V · 🇨🇦 CA Percentile in Healthcare Percentile in Canada | Izotropic Corporation IZO.CN · 🇨🇦 CA Percentile in Healthcare Percentile in Canada | Group median |
|---|---|---|---|---|---|---|---|---|---|
| Size | |||||||||
| Market cap (Better neither way: ranked highest first) | $18 Mlast known, Jul 30, 2023 · Market dataLast known value: no current one2nd of 8 | $17 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one3rd of 8 | $23 Mlast known, Jan 7, 2022 · Market dataLast known value: no current one1st of 8 | $13 Mlast known, Dec 25, 2022 · Market dataLast known value: no current one5th of 8 | $17 MOct 30, 2026 · Market data4th of 8 | $10 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one6th of 8 | $5 MOct 31, 2026 · Market data8th of 8 | $7 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one7th of 8 | $15 M8 ranked |
| Revenue (Better neither way: ranked highest first) | —— | —— | —— | —— | $29 MFY2025 · SEC1st of 2 | —— | $3 MFY2024 · SEC2nd of 2 | —— | $16 M2 ranked |
| Net income (Higher is better) | —— | —— | —— | —— | $-26 MFY2025 · SEC2nd of 2 | —— | $-0 MFY2024 · SEC1st of 2 | —— | $-13 M2 ranked |
| Employees (Better neither way: ranked highest first) | —— | —— | —— | —— | 299As on 2021 · Profileonly one with it | —— | —— | —— | 299— |
| Growth | |||||||||
| Market cap change, 30 days (Higher is better) | —— | —— | —— | —— | —— | —— | -7.8%30 days to Oct 31, 2026 · Market dataonly one with it | —— | -7.8%— |
| Revenue growth (Higher is better) | ———— | ———— | ———— | ———— | -7.4%FY2025 · SEC2nd of 215th14th | ———— | +31.8%FY2024 · SEC1st of 278th77th | ———— | +12.2%2 ranked |
| Revenue growth, 3 years a year (Higher is better) | ———— | ———— | ———— | ———— | +0.8%FY2025 · SEC2nd of 229th36th | ———— | +224.0%FY2024 · SEC1st of 2100th99th | ———— | +112.4%2 ranked |
| Margins and returns | |||||||||
| Gross margin (Higher is better) | ———— | ———— | ———— | ———— | 46.3%FY2025 · SEC1st of 232nd59th | ———— | 40.3%FY2024 · SEC2nd of 225th46th | ———— | 43.3%2 ranked |
| Operating margin (Higher is better) | ———— | ———— | ———— | ———— | -116.9%FY2025 · SEConly one with it21st9th | ———— | ———— | ———— | -116.9%— |
| Net margin (Higher is better) | ———— | ———— | ———— | ———— | -92.6%FY2025 · SEC2nd of 223rd10th | ———— | -14.4%FY2024 · SEC1st of 246th27th | ———— | -53.5%2 ranked |
| Free cash flow margin (Higher is better) | ———— | ———— | ———— | ———— | ———— | ———— | 17.6%FY2024 · SEConly one with it85th85th | ———— | 17.6%— |
| Return on equity (Higher is better) | ———— | ———— | ———— | ———— | -66.2%FY2025 · SEC2nd of 235th15th | ———— | -33.9%FY2024 · SEC1st of 252nd27th | ———— | -50.0%2 ranked |
| Valuation | |||||||||
| Price to sales (Better neither way: ranked highest first) | ———— | ———— | ———— | ———— | 0.5×price Oct 30, 2026 · Market data2nd of 29th17th | ———— | 1.3×price Oct 31, 2026 · Market data1st of 222nd31st | ———— | 0.9×2 ranked |
| Price to book (Better neither way: ranked highest first) | ———— | ———— | ———— | ———— | 0.4×price Oct 30, 2026 · Market data2nd of 24th4th | ———— | 3.3×price Oct 31, 2026 · Market data1st of 254th67th | ———— | 1.8×2 ranked |
| Free cash flow yield (Higher is better) | ———— | ———— | ———— | ———— | ———— | ———— | 13.3%price Oct 31, 2026 · Market dataonly one with it96th96th | ———— | 13.3%— |
| Scorecard | |||||||||
| Scorecard (Higher is better) | —— | —— | —— | —— | 5 of 19FY2025 · Scorecard2nd of 2 | —— | 8 of 15FY2024 · Scorecard1st of 2 | —— | 40% passed2 ranked |
| Valuation checks (Higher is better) | —— | —— | —— | —— | 2 of 4FY2025 · Scorecard2nd of 2 | —— | 3 of 5FY2024 · Scorecard1st of 2 | —— | 55% passed2 ranked |
| Growth checks (Higher is better) | —— | —— | —— | —— | 1 of 6FY2025 · Scorecard2nd of 2 | —— | 4 of 5FY2024 · Scorecard1st of 2 | —— | 48% passed2 ranked |
| Profitability checks (Higher is better) | —— | —— | —— | —— | 1 of 5FY2025 · Scorecard1st of 2 | —— | 0 of 3FY2024 · Scorecard2nd of 2 | —— | 10% passed2 ranked |
| Financial health checks (Higher is better) | —— | —— | —— | —— | 1 of 3FY2025 · Scorecard1st of 2 | —— | 0 of 1FY2024 · Scorecard2nd of 2 | —— | 17% passed2 ranked |
| Shareholder returns checks (Higher is better) | —— | —— | —— | —— | 0 of 1FY2025 · Scorecard2nd of 2 | —— | 1 of 1FY2024 · Scorecard1st of 2 | —— | 50% passed2 ranked |
| Ownership | |||||||||
| Held by institutions (Better neither way: ranked highest first) | —— | —— | —— | —— | 19.3%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are inonly one with it | —— | —— | —— | 19.3%— |
| Institutions holding (Better neither way: ranked highest first) | —— | —— | —— | —— | 362026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are inonly one with it | —— | —— | —— | 36— |
| Institutional holding, change over the quarter (Better neither way: ranked highest first) | —— | —— | —— | —— | -1.8 pp2026-Q2 against 2026-Q1 · 13Fonly one with it | —— | —— | —— | -1.8 pp— |
Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).
Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Akumin: TMX Group, TSX and TSXV listed issuers (monthly); Biomark Diagnostics Inc.: How market caps are worked out; Medivolve Inc.: How market caps are worked out; Cognetivity Neurosciences Ltd.: How market caps are worked out; Bionano Genomics, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; ASEP Medical Holdings Inc.: How market caps are worked out; Avricore Health Inc.: TMX Group, TSX and TSXV listed issuers (monthly); Izotropic Corporation: How market caps are worked out.
Where each stands in its sector and country: Operating margin#
The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.
| Company | Operating margin | In its sector | In its country |
|---|---|---|---|
| Akumin | — | — | — |
| Biomark Diagnostics Inc. | — | — | — |
| Medivolve Inc. | — | — | — |
| Cognetivity Neurosciences Ltd. | — | — | — |
| Bionano Genomics, Inc. | -116.9%FY2025 | 21st percentile in Healthcaremedian -7.8%, 678 companies | 9th percentile in USAmedian 3.4%, 2,607 companies |
| ASEP Medical Holdings Inc. | — | — | — |
| Avricore Health Inc. | — | — | — |
| Izotropic Corporation | — | — | — |
Revenue by fiscal year, and the rank in the group#
Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).
Revenue
Rank in the group
| Fiscal year | Akumin | Biomark Diagnostics Inc. | Medivolve Inc. | Cognetivity Neurosciences Ltd. | Bionano Genomics, Inc. | ASEP Medical Holdings Inc. | Avricore Health Inc. | Izotropic Corporation |
|---|---|---|---|---|---|---|---|---|
| 2025 | — | — | — | — | $29 MSEC | — | — | — |
| 2024 | — | — | — | — | $31 MSEC1st | — | $3 MSEC2nd | — |
| 2023 | — | — | — | — | $36 MSEC1st | — | $3 MSEC2nd | — |
| 2022 | — | — | — | — | $28 MSEC1st | — | $1 MSEC2nd | — |
| 2021 | — | — | — | — | $18 MSEC1st | — | $0 MSEC2nd | — |
| 2020 | — | — | — | — | $9 MSEC1st | — | $0 MSEC2nd | — |
| 2019 | — | — | — | — | $10 MSEC | — | — | — |
| 2018 | — | — | — | — | $12 MSEC | — | — | — |
| 2017 | — | — | — | — | $10 MSEC | — | — | — |
Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.
Suggested peers of Akumin#
Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.
- Biomark Diagnostics Inc.BUX.CN · 🇨🇦 CanadaSame industry: Diagnostics and Research · Similar size: $17 M market cap against $18 M · Same country: CanadaMarket cap $17 M (last known, Jan 5, 2024)95 of 100 (industry or sector 50 + size 30 + country 15)In the group
- Medivolve Inc.4NC.F · 🇨🇦 CanadaSame industry: Diagnostics and Research · Similar size: $23 M market cap against $18 M · Same country: CanadaMarket cap $23 M (last known, Jan 7, 2022)93 of 100 (industry or sector 50 + size 28 + country 15)In the group
- Cognetivity Neurosciences Ltd.1UB.F · 🇨🇦 CanadaSame industry: Diagnostics and Research · Similar size: $13 M market cap against $18 M · Same country: CanadaMarket cap $13 M (last known, Dec 25, 2022)93 of 100 (industry or sector 50 + size 28 + country 15)In the group
- Bionano Genomics, Inc.BNGO · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $17 M market cap against $18 M · Same region: Northern America · Ratios of the last two fiscal years on fileMarket cap $17 M (Oct 30, 2026) · revenue $29 M (year to December 2025)92 of 100 (industry or sector 50 + size 30 + country 7 + figures on file 5)In the group
- ASEP Medical Holdings Inc.ASEP.CN · 🇨🇦 CanadaSame industry: Diagnostics and Research · Similar size: $10 M market cap against $18 M · Same country: CanadaMarket cap $10 M (last known, Jan 5, 2024)91 of 100 (industry or sector 50 + size 26 + country 15)In the group
- Avricore Health Inc.AVCR.V · 🇨🇦 CanadaSame industry: Diagnostics and Research · Similar size: $5 M market cap against $18 M · Same country: Canada · Ratios of the last two fiscal years on fileMarket cap $5 M (Oct 31, 2026) · revenue $3 M (year to December 2024)91 of 100 (industry or sector 50 + size 21 + country 15 + figures on file 5)In the group
- Izotropic CorporationIZO.CN · 🇨🇦 CanadaSame industry: Diagnostics and Research · Similar size: $7 M market cap against $18 M · Same country: CanadaMarket cap $7 M (last known, Jan 5, 2024)89 of 100 (industry or sector 50 + size 24 + country 15)In the group
- SQI Diagnostics Inc.SQIDF · 🇨🇦 CanadaSame industry: Diagnostics and Research · Similar size: $51 M market cap against $18 M · Same country: CanadaMarket cap $51 M (last known, Jan 7, 2022)88 of 100 (industry or sector 50 + size 23 + country 15)+ Add
- Screenpro Security Inc.SCRN.CN · 🇨🇦 CanadaSame industry: Diagnostics and Research · Similar size: $6 M market cap against $18 M · Same country: CanadaMarket cap $6 M (last known, Jan 7, 2022)88 of 100 (industry or sector 50 + size 23 + country 15)+ Add
- BNB Plus Corp.BNBX · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $9 M market cap against $18 M · Same region: Northern America · Ratios of the last two fiscal years on fileMarket cap $9 M (last known, Jan 5, 2024) · revenue $2 M (year to September 2025)88 of 100 (industry or sector 50 + size 26 + country 7 + figures on file 5)+ Add
- Interpace Biosciences, Inc.IDXG · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $9 M market cap against $18 M · Same region: Northern America · Ratios of the last two fiscal years on fileMarket cap $9 M (last known, Jul 30, 2023) · revenue $39 M (year to December 2025)88 of 100 (industry or sector 50 + size 26 + country 7 + figures on file 5)+ Add
- Star Equity Holdings, Inc.STRR · 🇺🇸 USASame industry: Diagnostics and Research · Similar size: $37 M market cap against $18 M · Same region: Northern America · Ratios of the last two fiscal years on fileMarket cap $37 M (Oct 15, 2026) · revenue $172 M (year to December 2025)87 of 100 (industry or sector 50 + size 25 + country 7 + figures on file 5)+ Add
Any figure over the years, other peers or a saved group: open this group in the peer workspace.